Sartorius | SRT3 - Cash And Equivalent


Sartorius reported EUR291M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 155.55M 7.1M Jun/2026
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Avita Medical AUD 10.24M 1.98M Dec/2025
Dianthus Therapeutics USD 110.55M 517.12M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
IQVIA Holdings USD 1.91B 38M Jun/2026
Moderna USD 1.72B 185M Jun/2026
Organon & Co USD 1.12B 542M Mar/2026
Revvity USD 1.02B 162.62M Jun/2026
Sartorius EUR 291M 282.8M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Viatris USD 1.8B 481.8M Mar/2026
Xeris Pharmaceuticals USD 111.75M 708K Mar/2026